Literature DB >> 32147539

Comparative analysis of phenotypic and genotypic antibiotic susceptibility patterns in Mycobacterium avium complex.

Nils Wetzstein1, Thomas A Kohl2, Sönke Andres3, Tilman G Schultze4, Ari Geil5, Eunhee Kim6, Teodora Biciusca6, Christian Hügel7, Michael Hogardt8, Annette Lehn9, Maria J G T Vehreschild5, Timo Wolf5, Stefan Niemann2, Florian P Maurer10, Thomas A Wichelhaus4.   

Abstract

OBJECTIVE: Phenotypic (Sensititre Myco, pDST) and genotypic drug susceptibility testing (GenoType NTM DR, gDST) in M. avium complex (MAC) have become available as standardized assays, but comparable data is needed. This study aimed to investigate the phenotypic and genotypic drug susceptibility patterns in MAC clinical isolates.
METHODS: Overall, 98 isolates from 85 patients were included. pDST and gDST were performed on all isolates and results compared regarding specificity and sensitivity using pDST as a reference method. The impact of drug instability on pDST results was studied using a biological assay over 14 days. In addition, the evolution of antimicrobial resistance was investigated in sequential isolates of 13 patients.
RESULTS: Macrolide resistance was rare, 1.2% (95% CI 0.7-7.3) of isolates in the base cohort. No aminoglycoside resistances were found, but 14.1% of the studied isolates (95% CI 7.8-23.8) showed intermediate susceptibility. The GenoType NTM DR identified two out of four macrolide-resistant isolates. Antibiotic stability was demonstrated to be poor in rifampicin, rifabutin, and doxycycylin.
CONCLUSIONS: pDST results in NTM for unstable antibiotics must be interpreted with care. A combination of pDST and gDST will be useful for the guidance of antimicrobial therapy in MAC-disease.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  DST; Drug susceptibility testing; M. Intracellulare; M. avium; M. avium complex; M. chimaera; NTM; Non-tuberculous mycobacteria

Year:  2020        PMID: 32147539     DOI: 10.1016/j.ijid.2020.02.059

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  5 in total

1.  Antimicrobial Susceptibility and Phylogenetic Relations in a German Cohort Infected with Mycobacterium abscessus.

Authors:  Nils Wetzstein; Thomas A Kohl; Tilman G Schultze; Sönke Andres; Carla Bellinghausen; Christian Hügel; Volkhard A J Kempf; Annette Lehn; Michael Hogardt; Hubert Serve; Maria J G T Vehreschild; Timo Wolf; Stefan Niemann; Florian P Maurer; Thomas A Wichelhaus
Journal:  J Clin Microbiol       Date:  2020-11-18       Impact factor: 5.948

2.  Clinical and Microbiological Characteristics of Mycobacterium kansasii Pulmonary Infections in China.

Authors:  Yinjuan Guo; Yanhua Cao; Haican Liu; Jinghui Yang; Weiping Wang; Bingjie Wang; Meilan Li; Fangyou Yu
Journal:  Microbiol Spectr       Date:  2022-01-12

3.  What is new in BTS 2017 & ATS/ERS/ESCMID/IDSA 2020 guidelines on treatment of non-tuberculous mycobacterial pulmonary disease?

Authors:  Surendra Kumar Sharma; Vishwanath Upadhyay; Alladi Mohan
Journal:  Indian J Med Res       Date:  2021-03       Impact factor: 5.274

4.  In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates.

Authors:  Siran Lin; Wenya Hua; Shiyong Wang; Yu Zhang; Xinchang Chen; Hong Liu; Lingyun Shao; Jiazhen Chen; Wenhong Zhang
Journal:  BMC Microbiol       Date:  2022-07-08       Impact factor: 4.465

Review 5.  Mycobacterium chimaera: a report of 2 new cases and literature review.

Authors:  Alice Natanti; Marco Palpacelli; Marco Valsecchi; Adriano Tagliabracci; Mauro Pesaresi
Journal:  Int J Legal Med       Date:  2021-06-29       Impact factor: 2.686

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.